These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27125715)

  • 1. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab.
    Wichmann A; Krugliak Cleveland N; Rubin DT
    Am J Gastroenterol; 2016 Apr; 111(4):577. PubMed ID: 27125715
    [No Abstract]   [Full Text] [Related]  

  • 2. Vedolizumab for Crohn's disease.
    Mosli MH; Feagan BG
    Expert Opin Biol Ther; 2013 Mar; 13(3):455-63. PubMed ID: 23394379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crohn's disease with anorectal stenosis successfully treated with vedolizumab.
    Urlep D; Orel R
    World J Pediatr; 2017 Aug; 13(4):394-395. PubMed ID: 28540693
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.
    Huff-Hardy K; Bedair M; Vazquez R; Burstein E
    Inflamm Bowel Dis; 2017 Oct; 23(10):E49. PubMed ID: 28858074
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease.
    Rath T; Bojarski C; Neurath MF; Atreya R
    Gastrointest Endosc; 2017 Aug; 86(2):406-408. PubMed ID: 28137597
    [No Abstract]   [Full Text] [Related]  

  • 9. Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab.
    Pouldar D; Elsensohn A; Ortenzio F; Shiu J; McLeod M; de Feraudy S
    Am J Dermatopathol; 2018 Mar; 40(3):e36-e37. PubMed ID: 28953016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab in the treatment of Crohn's disease.
    Tarabar D; Hirsch A; Rubin DT
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles, measles vaccination, and Crohn's disease. Crohn's disease has not increased in Finland.
    Pebody RG; Paunio M; Ruutu P
    BMJ; 1998 Jun; 316(7146):1745-6. PubMed ID: 9652932
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome.
    Al-Sukaiti N; Reid B; Lavi S; Al-Zaharani D; Atkinson A; Roifman CM; Grunebaum E
    J Allergy Clin Immunol; 2010 Oct; 126(4):868-9. PubMed ID: 20810153
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis".
    Attauabi M; Seidelin JB; Burisch J
    Dig Liver Dis; 2023 Feb; 55(2):300-301. PubMed ID: 36464612
    [No Abstract]   [Full Text] [Related]  

  • 17. Sweet syndrome after treatment with vedolizumab in a patient with Crohn's disease.
    Martínez Andrés B; Sastre Lozano V; Sánchez Melgarejo JF
    Rev Esp Enferm Dig; 2018 Aug; 110(8):530. PubMed ID: 29900741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.
    de Menezes Martins R; Curran B; Maia Mde L; Ribeiro Md; Camacho LA; da Silva Freire M; Yamamura AM; Siqueira MM; Lemos MC; de Albuquerque EM; von Doellinger Vdos R; Homma A; Saganic L; Jarrahian C; Royals M; Zehrung D
    Contemp Clin Trials; 2015 Mar; 41():1-8. PubMed ID: 25476584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukoapheresis in Crohn's disease: the final curtain?
    Peyrin-Biroulet L; Danese S
    Gut; 2013 Apr; 62(4):487-8. PubMed ID: 22892296
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.